Novo Nordisk A/S (B Shares) ADRhedged
NVOH - ETF AI Analysis
Top Page
Novo Nordisk A/S (B Shares) ADRhedged (NVOH)
NVOH’s rating suggests it is a solid but not perfect way to gain exposure to Novo Nordisk, with overall quality supported by its main holding. The fund is heavily concentrated in NVO, whose strong financial performance, long-term growth focus, and attractive dividend help drive the rating, but bearish technical signals and recent challenges like market share loss and restructuring keep the fund from scoring higher. The key risk for investors is this very high concentration in a single company, which means the ETF’s fortunes are closely tied to Novo Nordisk’s future performance.
NVOH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 3.94M
- Region
- Europe
- Expense Ratio
- 0.19%
- Beta
- 0.95
- Issuer
- ADRhedged
- Inception Date
- Jan 07, 2025
- Dividend Yield
- 6.55%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
NVOH Summary
NVOH is an ETF that focuses on one main company: Novo Nordisk, a global leader in diabetes and obesity treatments. It doesn’t track a broad index, but instead gives targeted exposure to the health care and pharmaceuticals theme, mainly through Novo Nordisk shares. Investors might consider NVOH if they believe in the long-term growth of treatments for chronic diseases and want a simple way to invest in a major player in that space, with some protection against currency swings. A key risk is that the fund is heavily concentrated in a single company, so its value can rise or fall sharply based on Novo Nordisk’s performance.
How much will it cost me?
This ETF has an expense ratio of 0.19%, which means you’ll pay about $1.90 per year for every $1,000 invested. That’s slightly higher than the cheapest broad-market index ETFs, mainly because this fund is very specialized and focused on a single company and currency hedging strategy.
What would affect this ETF?
Future performance of this Denmark-focused health care ETF will largely depend on how well Novo Nordisk continues to grow its diabetes and obesity treatments, benefits from new drug approvals, and navigates global demand for pharmaceuticals. On the downside, tighter drug pricing rules, competition from other pharmaceutical companies, changes in health care regulations, or broader economic and interest rate shifts that reduce investor appetite for European health care stocks could hurt returns, and the heavy concentration in a single company increases the impact of any negative news about Novo Nordisk.
NVOH Top 10 Holdings
This ETF is essentially a one-stock story: Novo Nordisk dominates the portfolio and sets the tone for performance. After a strong recent pop, the stock’s longer-term trend has been more mixed, with earlier weakness still weighing on year-to-date results. That means when Novo Nordisk is rising on optimism around its diabetes and obesity drugs, the fund looks strong; when the stock stumbles on technical or competitive concerns, the ETF feels it directly. Sector-wise, it’s a pure play on European pharmaceuticals, with all roads leading back to Denmark.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Novo Nordisk | 92.76% | $3.73M | $182.02B | -15.32% | 73Outperform |
NVOH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For NVOH, the sentiment is Positive. The current price of 23.80 is above the 20-day moving average (MA) of 22.60, above the 50-day MA of 22.41, and above the 200-day MA of 23.28, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 61.85 is Neutral, neither overbought nor oversold. The STOCH value of 39.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NVOH.
NVOH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $23.80 | $24.50(2.93% Upside) | $3.94M | 0.19% | 69Neutral | |
| $10.77 | $17.56(63.03% Upside) | $4.61M | 0.19% | 76Outperform | |
| $8.27 | $12.42(50.16% Upside) | $4.23M | 0.19% | 67Neutral | |
| $101.18 | ― | $3.02M | 0.19% | 76Outperform | |
| $73.43 | $85.44(16.35% Upside) | $2.18M | 0.19% | 65Neutral | |
| $72.64 | $82.99(14.26% Upside) | $719.07K | 0.19% | 75Outperform |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NVOH | Novo Nordisk A/S (B Shares) ADRhedged | 23.80 | -1.39 | -5.53% | |
| ASMH | ASML Holding NV ADRhedged | 10.77 | 3.92 | 57.21% | |
| ARMH | Arm Holdings PLC ADRhedged | 8.27 | 2.24 | 37.20% | |
| HSBH | HSBC Holdings plc ADRhedged | 101.18 | 22.79 | 29.07% | |
| BPH | BP p.l.c. ADRhedged | 73.43 | 16.34 | 28.62% | |
| GSKH | GSK plc ADRhedged | 72.64 | 6.03 | 9.05% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
